Glioblastoma Multiforme (GBM) Treatment Market to Grow at 11.4% CAGR, Driven by Awareness Programs: Transparency Market Research

ALBANY, N.Y.--()--The report “Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022” from Transparency Market Research (TMR) delivers analysis of key trends of the global glioblastoma multiforme treatment market. According to this report, the global glioblastoma multiforme (GBM) treatment market will expand at a marked CAGR of 11.4% during the forecast period of 2014 to 2022. In 2013, the global glioblastoma multiforme (GBM) treatment market was estimated at US$0.34 billion and is expected to be worth US$0.91 billion by 2022.

Browse Report: http://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html

The rising geriatric population, introduction of several novel therapies owing to a strong pipeline, and several government and NGOs creating awareness about glioblastoma multiforme (GBM) are driving the global glioblastoma multiforme market. Nevertheless, reduced overall survival period delivered by FDA-approved treatments, along with the highly resistant nature of GBM to DNA-modifying agents, will suppress the market.

Request Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=4807

The global glioblastoma multiforme (GBM) treatment market is segmented by drugs into carmustine (BiCNU), temozolomide (Temodar and Temodal and Temcad), and bevacizumab (Avastin). Two of the drugs in Phase III of the development pipeline are Rindopepimut (CDX-110) and DCVax. Some of the drugs in the early stage of the pipeline for glioblastoma multiforme are Cotar, AV0113, MM-398, Endostatin, and Crenolanib. In 2013, temozolomide dominated the global glioblastoma treatment market, due to the therapeutic benefit of methylated/alkylated DNA.

Press Release: http://www.transparencymarketresearch.com/pressrelease/pipeline-review-of-glioblastoma-treatment-market.htm

Geographically, the global glioblastoma multiforme market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2013, North America dominated the global GBM treatment market due to the rising incidence of GBM. The key companies operating in this market are Merck & Co., LLC, Arbor Pharmaceuticals, and F. Hoffman-Le Roche.

Other Reports:

About TMR

Transparency Market Research (TMR) is a U.S. based market intelligence company driven by high-pedigree consultants and researchers. TMR leverages its Syndicated Research, Custom Research, and Market Consulting expertise to help businesses make accurate decisions. TMR’s exclusive blend of quantitative forecasting and trends analysis draws on proprietary data sources and techniques, while their data repository is continuously updated to reflect the latest trends.

Contacts

Transparency Market Research
Mr. Nachiket Ghumare, +1-518-618-1030
USA-Canada Toll Free: 866-552-3453
sales@transparencymarketresearch.com
http://www.transparencymarketresearch.com/

Release Summary

Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022

Contacts

Transparency Market Research
Mr. Nachiket Ghumare, +1-518-618-1030
USA-Canada Toll Free: 866-552-3453
sales@transparencymarketresearch.com
http://www.transparencymarketresearch.com/